GlassScriptPhysician profile
Albert Samandarov
NPI 1528364353
$433.66
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.21 · 2021: $156 · 2022: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $308.98 | 2019-2022 | |
| Horizon Therapeutics Plc | $37.80 | 2019-2022 | |
| Nevro Corp. | $22.87 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.96 | 2021 | |
| Treace Medical Concepts, INC. | $15.87 | 2022 | |
| Bioventus LLC | $14.11 | 2019 | |
| Medtronic Vascular, INC. | $13.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Samandarov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.